-0.03 | -3.88%
BACTERIN INTL HOLDINGS INC's gross profit margin for the first quarter of its fiscal year 2013 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. BACTERIN INTL HOLDINGS INC has average liquidity. Currently, the Quick Ratio is 1.10 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 70.42% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 8.62 | 7.77 |
| EBITDA ($mil) | 0.0 | -1.06 |
| EBIT ($mil) | -1.23 | -1.27 |
| Net Income ($mil) | -1.67 | -1.05 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 2.12 | 1.36 |
| Total Assets ($mil) | 32.75 | 26.71 |
| Total Debt ($mil) | 15.13 | 8.57 |
| Equity ($mil) | 2.66 | 8.99 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | 62.56 | 77.3 |
| EBITDA Margin | 0.0 | -13.62 |
| Operating Margin | -14.31 | -16.38 |
| Sales Turnover | 1.03 | 1.19 |
| Return on Assets | -25.45 | -33.58 |
| Return on Equity | -313.73 | -99.83 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 2.8 | 1.72 |
| Debt/Capital | 0.85 | 0.49 |
| Interest Expense | 1.06 | 0.17 |
| Interest Coverage | -1.16 | -7.44 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 42.96 | 42.52 |
| Div / share | 0.0 | 0.0 |
| EPS | -0.04 | -0.03 |
| Book value / share | 0.06 | 0.21 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 172600.0 | 138902.0 |
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 13.59 indicates a significant premium versus the S&P 500 average of 2.40 and a significant premium versus the industry average of 3.58. The price-to-sales ratio is below the S&P 500 average and is well below the industry average, indicating a discount. After reviewing these and other key valuation criteria, BACTERIN INTL HOLDINGS INC proves to trade at a premium to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BONE NM | Peers 21.52 | BONE NM | Peers 14.01 | |||||||||||||||||||||
|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. BONE's P/E is negative making this valuation measure meaningless. |
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. BONE's P/CF is negative making the measure meaningless. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| BONE NM | Peers 21.19 | BONE NA | Peers 1.54 | |||||||||||||||||||||
|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings. BONE's ratio is negative making this valuation measure meaningless. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| BONE 13.59 | Peers 3.58 | BONE 17.40 | Peers -1.37 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. BONE is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. BONE is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| BONE 1.07 | Peers 6.42 | BONE 5.98 | Peers 6.86 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. BONE is trading at a significant discount to its industry on this measurement. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. BONE trails its peers on the basis of sales growth |
|||||||||||||||||||||||
